Cargando…
A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation
BACKGROUND: Prostaglandin E1 (PGE1) has been reported to maintain adequate oxygenation among patients under 60% FiO(2) one-lung ventilation (OLV). This research aimed to explore whether PGE1 is safe in pulmonary shunt and oxygenation under 40% FiO(2) OLV and provide a reference concentration of PGE1...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759228/ https://www.ncbi.nlm.nih.gov/pubmed/35027012 http://dx.doi.org/10.1186/s12890-022-01831-4 |
_version_ | 1784633068895600640 |
---|---|
author | Li, Pengyi Gu, Lianbing Tan, Jing Song, Zhenghuan Bian, Qingming Jiao, Dian Xu, Zeping Wang, Lijun |
author_facet | Li, Pengyi Gu, Lianbing Tan, Jing Song, Zhenghuan Bian, Qingming Jiao, Dian Xu, Zeping Wang, Lijun |
author_sort | Li, Pengyi |
collection | PubMed |
description | BACKGROUND: Prostaglandin E1 (PGE1) has been reported to maintain adequate oxygenation among patients under 60% FiO(2) one-lung ventilation (OLV). This research aimed to explore whether PGE1 is safe in pulmonary shunt and oxygenation under 40% FiO(2) OLV and provide a reference concentration of PGE1. METHODS: Totally 90 esophageal cancer patients treated with thoracotomy were enrolled in this study, randomly divided into three groups (n = 30/group): Group A (60% FiO(2) and 0.1 µg/kg PGE1), Group B (40% FiO(2) and 0.1 µg/kg PGE1), and Group C (40% FiO(2), 0.2 µg/kg PGE1). Primary outcomes were oxygenation and pulmonary shunt during OLV. Secondary outcomes included oxidative stress after OLV. RESULTS: During OLV, patients in Group C and B had lower levels of PaO(2), SaO(2), SpO(2), MAP, and Qs/Qt than those in Group A (P < 0.05). At T2 (OLV 10 min), patients in Group C and B exhibited a lower level of PaO(2)/FiO(2) than those in Group A, without any statistical difference at other time points. The IL-6 levels of patients in different groups were different at T8 (F = 3.431, P = 0.038), with IL-6 in Group C being lower than that in Group B and A. MDA levels among the three groups differed at T5 (F = 4.692, P = 0.012) and T7 (F = 5.906, P = 0.004), with the MDA level of Group C being lower than that of Group B and A at T5, and the MDA level of Group C and B being lower than that of Group A at T7. In terms of TNF-α level, patients in Group C had a lower level than those in Group B and A at T8 (F = 3.598, P = 0.033). Compared with patients who did not use PGE1, patients in Group C had comparable complications and lung infection scores. CONCLUSION: The concentration of FiO(2) could be reduced from 60 to 40% to maintain oxygenation. 40% FiO(2) + 0.2 µg/kg PGE1 is recommended as a better combination on account of its effects on the inflammatory factors. Trial registration: Chictr.org.cn identifier: ChiCTR1800018288, 09/09/2018. |
format | Online Article Text |
id | pubmed-8759228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87592282022-01-18 A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation Li, Pengyi Gu, Lianbing Tan, Jing Song, Zhenghuan Bian, Qingming Jiao, Dian Xu, Zeping Wang, Lijun BMC Pulm Med Research BACKGROUND: Prostaglandin E1 (PGE1) has been reported to maintain adequate oxygenation among patients under 60% FiO(2) one-lung ventilation (OLV). This research aimed to explore whether PGE1 is safe in pulmonary shunt and oxygenation under 40% FiO(2) OLV and provide a reference concentration of PGE1. METHODS: Totally 90 esophageal cancer patients treated with thoracotomy were enrolled in this study, randomly divided into three groups (n = 30/group): Group A (60% FiO(2) and 0.1 µg/kg PGE1), Group B (40% FiO(2) and 0.1 µg/kg PGE1), and Group C (40% FiO(2), 0.2 µg/kg PGE1). Primary outcomes were oxygenation and pulmonary shunt during OLV. Secondary outcomes included oxidative stress after OLV. RESULTS: During OLV, patients in Group C and B had lower levels of PaO(2), SaO(2), SpO(2), MAP, and Qs/Qt than those in Group A (P < 0.05). At T2 (OLV 10 min), patients in Group C and B exhibited a lower level of PaO(2)/FiO(2) than those in Group A, without any statistical difference at other time points. The IL-6 levels of patients in different groups were different at T8 (F = 3.431, P = 0.038), with IL-6 in Group C being lower than that in Group B and A. MDA levels among the three groups differed at T5 (F = 4.692, P = 0.012) and T7 (F = 5.906, P = 0.004), with the MDA level of Group C being lower than that of Group B and A at T5, and the MDA level of Group C and B being lower than that of Group A at T7. In terms of TNF-α level, patients in Group C had a lower level than those in Group B and A at T8 (F = 3.598, P = 0.033). Compared with patients who did not use PGE1, patients in Group C had comparable complications and lung infection scores. CONCLUSION: The concentration of FiO(2) could be reduced from 60 to 40% to maintain oxygenation. 40% FiO(2) + 0.2 µg/kg PGE1 is recommended as a better combination on account of its effects on the inflammatory factors. Trial registration: Chictr.org.cn identifier: ChiCTR1800018288, 09/09/2018. BioMed Central 2022-01-13 /pmc/articles/PMC8759228/ /pubmed/35027012 http://dx.doi.org/10.1186/s12890-022-01831-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Li, Pengyi Gu, Lianbing Tan, Jing Song, Zhenghuan Bian, Qingming Jiao, Dian Xu, Zeping Wang, Lijun A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation |
title | A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation |
title_full | A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation |
title_fullStr | A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation |
title_full_unstemmed | A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation |
title_short | A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation |
title_sort | randomised controlled trial on roles of prostaglandin e1 nebulization among patients undergoing one lung ventilation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759228/ https://www.ncbi.nlm.nih.gov/pubmed/35027012 http://dx.doi.org/10.1186/s12890-022-01831-4 |
work_keys_str_mv | AT lipengyi arandomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT gulianbing arandomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT tanjing arandomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT songzhenghuan arandomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT bianqingming arandomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT jiaodian arandomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT xuzeping arandomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT wanglijun arandomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT lipengyi randomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT gulianbing randomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT tanjing randomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT songzhenghuan randomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT bianqingming randomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT jiaodian randomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT xuzeping randomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation AT wanglijun randomisedcontrolledtrialonrolesofprostaglandine1nebulizationamongpatientsundergoingonelungventilation |